| Year |
Citation |
Score |
| 2022 |
Gamal W, Sahakian E, Pinilla-Ibarz J. The role of Th17 cells in chronic lymphocytic leukemia: friend or foe? Blood Advances. PMID 36574293 DOI: 10.1182/bloodadvances.2022008985 |
0.381 |
|
| 2022 |
Maharaj K, Uriepero A, Sahakian E, Pinilla-Ibarz J. Regulatory T cells (Tregs) in lymphoid malignancies and the impact of novel therapies. Frontiers in Immunology. 13: 943354. PMID 35979372 DOI: 10.3389/fimmu.2022.943354 |
0.365 |
|
| 2021 |
Mostofa A, Distler A, Meads MB, Sahakian E, Powers JJ, Achille A, Noyes D, Wright G, Fang B, Izumi V, Koomen J, Rampakrishnan R, Nguyen TP, De Avila G, Silva AS, et al. Plasma cell dependence on histone/protein deacetylase 11 reveals a therapeutic target in multiple myeloma. Jci Insight. PMID 34793338 DOI: 10.1172/jci.insight.151713 |
0.407 |
|
| 2021 |
Chen J, Cheng F, Sahakian E, Powers J, Wang Z, Tao J, Seto E, Pinilla-Ibarz J, Sotomayor EM. HDAC11 regulates expression of C/EBPβ and immunosuppressive molecules in myeloid-derived suppressor cells. Journal of Leukocyte Biology. 109: 891-900. PMID 33866588 DOI: 10.1002/JLB.1A1119-606RRR |
0.357 |
|
| 2020 |
Maharaj K, Powers JJ, Mediavilla-Varela M, Achille A, Gamal W, Quayle S, Jones SS, Sahakian E, Pinilla-Ibarz J. HDAC6 Inhibition Alleviates CLL-Induced T-Cell Dysfunction and Enhances Immune Checkpoint Blockade Efficacy in the Eμ-TCL1 Model. Frontiers in Immunology. 11: 590072. PMID 33329575 DOI: 10.3389/fimmu.2020.590072 |
0.764 |
|
| 2020 |
Maharaj K, Powers JJ, Achille A, Mediavilla-Varela M, Gamal W, Burger KL, Fonseca R, Jiang K, Miskin HP, Maryanski D, Monastyrskyi A, Duckett DR, Roush WR, Cleveland JL, Sahakian E, et al. The dual PI3Kδ/CK1ε inhibitor umbralisib exhibits unique immunomodulatory effects on CLL T cells. Blood Advances. 4: 3072-3084. PMID 32634240 DOI: 10.1182/Bloodadvances.2020001800 |
0.738 |
|
| 2019 |
Yue L, Sharma V, Horvat NP, Akuffo AA, Beatty MS, Murdun C, Colin C, Billington J, Goodheart WE, Sahakian E, Zhang L, Powers JJ, Amin NE, Lambert-Showers QT, Darville LN, et al. HDAC11 Deficiency or Inhibition Disrupts Oncogene-Induced Stress Hematopoiesis in Myeloproliferative Neoplasms. Blood. PMID 31750881 DOI: 10.1182/Blood.2019895326 |
0.47 |
|
| 2019 |
Knox T, Sahakian E, Banik D, Hadley M, Palmer E, Noonepalle S, Kim J, Powers J, Gracia-Hernandez M, Oliveira V, Cheng F, Chen J, Barinka C, Pinilla-Ibarz J, Lee NH, et al. Author Correction: Selective HDAC6 inhibitors improve anti-PD-1 immune checkpoint blockade therapy by decreasing the anti-inflammatory phenotype of macrophages and down-regulation of immunosuppressive proteins in tumor cells. Scientific Reports. 9: 14824. PMID 31597938 DOI: 10.1038/S41598-019-51403-6 |
0.386 |
|
| 2019 |
Knox T, Sahakian E, Banik D, Hadley M, Palmer E, Noonepalle S, Kim J, Powers J, Gracia-Hernandez M, Oliveira V, Cheng F, Chen J, Barinka C, Pinilla-Ibarz J, Lee NH, et al. Selective HDAC6 inhibitors improve anti-PD-1 immune checkpoint blockade therapy by decreasing the anti-inflammatory phenotype of macrophages and down-regulation of immunosuppressive proteins in tumor cells. Scientific Reports. 9: 6136. PMID 30992475 DOI: 10.1038/s41598-019-42237-3 |
0.35 |
|
| 2019 |
Sharma V, Yue L, Horvat NP, Christodoulidou A, Akuffo AA, Beatty M, Murdun C, Billington J, Goodheart WE, Sahakian E, Zhang L, Powers JJ, Amin NE, Lambert-Showers QT, Darville L, et al. Selective Targeting of Histone Deacetylase 11 Disables Metabolism of Myeloproliferative Neoplasms Blood. 134: 474-474. DOI: 10.1182/Blood-2019-127235 |
0.473 |
|
| 2019 |
Knox TJ, Sahakian E, Banik D, Hadley M, Palmer E, Kim J, Noonepalle S, Powers J, Gracia-Hernandez M, Oliveira V, Cheng F, Chen J, Barinka C, Pinilla-Ibarz J, Lee N, et al. Abstract LB-074: Priming the tumor microenvironment with epigenetic modifiers to overcome resistance to immune checkpoint inhibitors Cancer Research. 79. DOI: 10.1158/1538-7445.Sabcs18-Lb-074 |
0.457 |
|
| 2019 |
Maharaj K, Powers J, Achille A, Sahakian E, Pinilla-Ibarz J. Abstract 4723: Combinatorial efficacy of anti-PD1 treatment and selective histone deacetylase 6 (HDAC6) inhibition in chronic lymphocytic leukemia (CLL) Cancer Research. 79: 4723-4723. DOI: 10.1158/1538-7445.Am2019-4723 |
0.481 |
|
| 2018 |
Maharaj K, Powers JJ, Achille A, Deng S, Fonseca R, Pabon-Saldana M, Quayle SN, Jones SS, Villagra A, Sotomayor EM, Sahakian E, Pinilla-Ibarz J. Silencing of HDAC6 as a therapeutic target in chronic lymphocytic leukemia. Blood Advances. 2: 3012-3024. PMID 30425065 DOI: 10.1182/Bloodadvances.2018020065 |
0.526 |
|
| 2018 |
Sweet K, Hazlehurst L, Sahakian E, Powers J, Nodzon L, Kayali F, Hyland K, Nelson A, Pinilla-Ibarz J. A phase I clinical trial of ruxolitinib in combination with nilotinib in chronic myeloid leukemia patients with molecular evidence of disease. Leukemia Research. 74: 89-96. PMID 30340199 DOI: 10.1016/J.Leukres.2018.10.002 |
0.379 |
|
| 2018 |
Mostofa A, Distler A, Meads MB, Sahakian E, Powers JJ, Nguyen T, Alsina M, Nishihori T, Baz R, Pinilla Ibarz J, Sotomayor E, Shain KH, Brayer JB. Functional Analysis of HDAC11 in Plasma Cell Development and Multiple Myeloma Survival Blood. 132: 3223-3223. DOI: 10.1182/Blood-2018-99-119119 |
0.568 |
|
| 2018 |
Chen J, Cheng F, Wang M, Sahakian E, Powers JJ, Pinilla Ibarz J, Smith MR, Sotomayor E. Loss of HDAC11 Promotes Myeloid-Derived Suppressor Cells Inhibition of T Cell Function in a Murine Lymphoma Microenvironment Blood. 132: 1105-1105. DOI: 10.1182/Blood-2018-99-117007 |
0.525 |
|
| 2018 |
Chen J, Cheng F, Sahakian E, Powers J, Wang Z, Villagra A, Pinilla-Ibarz J, Sotomayor EM. Abstract 4967: HDAC11 function as a transcriptional regulator in immature myeloid cells to myeloid-derived suppressor cells transition Cancer Research. 78: 4967-4967. DOI: 10.1158/1538-7445.Am2018-4967 |
0.528 |
|
| 2018 |
Knox T, Sahakian E, Banik D, Hadley M, Palmer E, Kim J, Powers J, Shah S, Lowe A, Pinilla J, Sotomayor E, Lee N, Kozikowski A, Villagra AV. Abstract 1703: The HDAC6 inhibitor Nexturastat A improvesin vivoPD-1 immune blockade Immunology. DOI: 10.1158/1538-7445.Am2018-1703 |
0.352 |
|
| 2017 |
Maharaj K, Sahakian E, Pinilla-Ibarz J. Emerging role of BCR signaling inhibitors in immunomodulation of chronic lymphocytic leukemia. Blood Advances. 1: 1867-1875. PMID 29296833 DOI: 10.1182/Bloodadvances.2017006809 |
0.484 |
|
| 2017 |
Sahakian E, Chen J, Powers JJ, Chen X, Maharaj K, Deng SL, Lienlaf M, Wang HW, Cheng F, Sodré AL, Distler A, Xing L, Perez-Villarroel P, Wei S, Villagra A, et al. Essential role for histone deacetylase 11 (HDAC11) in neutrophil biology. Journal of Leukocyte Biology. PMID 28550123 DOI: 10.1189/Jlb.1A0415-176Rrr |
0.411 |
|
| 2017 |
Distler A, Brayer JB, Meads M, Sahakian E, Powers JJ, Alsina M, Nishihori T, Baz RC, Pinilla-Ibarz J, Sotomayor EM, Shain KH. HDAC11 as a candidate therapeutic target in multiple myeloma. Journal of Clinical Oncology. 35: 8029-8029. DOI: 10.1182/Blood.V130.Suppl_1.1800.1800 |
0.546 |
|
| 2017 |
Knox T, Sahakian E, Nair J, Kim J, Banik D, Hadley M, Powers J, Cheng F, Shen S, Pinilla J, Weber J, Kozikowski A, Sotomayor E, Villagra A. Abstract 4055: Enhancing anti-PD-1 immune blockade in melanoma through selective inhibition of histone deacetylase 6 Cancer Research. 77: 4055-4055. DOI: 10.1158/1538-7445.Am2017-4055 |
0.415 |
|
| 2016 |
Chen J, Sahakian E, Powers J, Lienlaf M, Perez-Villarroel P, Knox T, Villagra A. Erratum to: Functional Analysis of Histone Deacetylase 11 (HDAC11). Methods in Molecular Biology (Clifton, N.J.). 1436: E1. PMID 27535557 DOI: 10.1007/978-1-4939-3667-0_22 |
0.306 |
|
| 2016 |
Villagra A, Sahakian E, Seto E. Preparation and Biochemical Analysis of Classical Histone Deacetylases. Methods in Enzymology. 573: 161-81. PMID 27372753 DOI: 10.1016/Bs.Mie.2016.04.005 |
0.344 |
|
| 2016 |
Chen J, Sahakian E, Powers J, Lienlaf M, Perez-Villarroel P, Knox T, Villagra A. Functional Analysis of Histone Deacetylase 11 (HDAC11). Methods in Molecular Biology (Clifton, N.J.). 1436: 147-65. PMID 27246214 DOI: 10.1007/978-1-4939-3667-0_11 |
0.381 |
|
| 2016 |
Powers J, Lienlaf M, Perez-Villarroel P, Deng S, Knox T, Villagra A, Sahakian E. Expression and Function of Histone Deacetylase 10 (HDAC10) in B Cell Malignancies. Methods in Molecular Biology (Clifton, N.J.). 1436: 129-45. PMID 27246213 DOI: 10.1007/978-1-4939-3667-0_10 |
0.514 |
|
| 2016 |
Lienlaf M, Perez-Villarroel P, Knox T, Pabon M, Sahakian E, Powers J, Woan KV, Lee C, Cheng F, Deng S, Smalley KS, Montecino M, Kozikowski A, Pinilla-Ibarz J, Sarnaik A, et al. Essential role of HDAC6 in the regulation of PD-L1 in melanoma. Molecular Oncology. PMID 26775640 DOI: 10.1016/J.Molonc.2015.12.012 |
0.464 |
|
| 2016 |
Maharaj KK, Powers JJ, Pabon-Saldana M, Fonseca R, Achille A, Deng S, Miskin HP, Maryanski D, Sahakian E, Pinilla-Ibarz J. Modulation of T Cell Compartment in a Preclinical CLL Murine Model By a Selective PI3K Delta Inhibitor, TGR-1202 Blood. 128: 3236-3236. DOI: 10.1182/Blood.V128.22.3236.3236 |
0.471 |
|
| 2016 |
Maharaj KK, Powers JJ, Deng S, Achille A, Pabon-Saldana M, Fonseca R, Quayle SN, Jones SS, Sahakian E, Pinilla-Ibarz J. Combinatorial Effect of HDAC6i and Ibrutinib Therapy in CLL Murine Model Blood. 128: 2035-2035. DOI: 10.1182/Blood.V128.22.2035.2035 |
0.485 |
|
| 2016 |
Sweet KL, Hazlehurst L, Sahakian E, Powers JJ, Nodzon L, Kayali F, Hyland K, Nelson A, Pinilla-Ibarz J. A Phase I Study of Ruxolitinib Plus Nilotinib in Chronic Phase CML Patients with Molecular Evidence of Disease Blood. 128: 1892-1892. DOI: 10.1182/Blood.V128.22.1892.1892 |
0.324 |
|
| 2016 |
Maharaj KK, Powers J, Fonseca R, Miskin H, Maryanski D, Sahakian E, Pinilla-Ibarz J. Abstract 545: Differential regulation of human T-cells by TGR-1202, a novel PI3Kδ inhibitor Cancer Research. 76: 545-545. DOI: 10.1158/1538-7445.Am2016-545 |
0.506 |
|
| 2016 |
Sahakian E, Maharaj K, Powers J, Fonesca RM, Deng S, Pinilla-Ibraz J, Quayle SN, Jones SS. Abstract 4485: Regulation of chronic lymphocytic leukemia (CLL) immunobiology by histone deacetylase 6 (HDAC6) Cancer Research. 76: 4485-4485. DOI: 10.1158/1538-7445.Am2016-4485 |
0.577 |
|
| 2016 |
Knox T, Lienlaf M, Perez P, Pabon M, Lee C, Cheng F, Sahakian E, Powers J, Deng S, Keiran S, Kozikowski A, Pinilla J, Sarnaik A, Seto E, Weber J, et al. Abstract 2331: HDAC6, new role as master regulator of PD-L1 and immune-related pathways Cancer Research. 76: 2331-2331. DOI: 10.1158/1538-7445.Am2016-2331 |
0.442 |
|
| 2015 |
Woan KV, Lienlaf M, Perez-Villaroel P, Lee C, Cheng F, Knox T, Woods DM, Barrios K, Powers J, Sahakian E, Wang HW, Canales J, Marante D, Smalley KS, Bergman J, et al. Targeting histone deacetylase 6 mediates a dual anti-melanoma effect: Enhanced antitumor immunity and impaired cell proliferation. Molecular Oncology. PMID 25957812 DOI: 10.1016/J.Molonc.2015.04.002 |
0.57 |
|
| 2015 |
Sahakian E, Powers JJ, Chen J, Deng SL, Cheng F, Distler A, Woods DM, Rock-Klotz J, Sodre AL, Youn JI, Woan KV, Villagra A, Gabrilovich D, Sotomayor EM, Pinilla-Ibarz J. Histone deacetylase 11: A novel epigenetic regulator of myeloid derived suppressor cell expansion and function. Molecular Immunology. 63: 579-85. PMID 25155994 DOI: 10.1016/J.Molimm.2014.08.002 |
0.472 |
|
| 2015 |
Brayer J, Sahakian E, Nguyen D, Powers J, Meads M, Deng S, Distler A, Alsina M, Nishihori T, Baz R, Villagra A, Pinilla-Ibarz J, Sotomayor E, Shain K. Histone deacetylase 11 (HDAC11) is critical for plasma cell development and multiple myeloma survival Clinical Lymphoma Myeloma and Leukemia. 15: e222-e223. DOI: 10.1016/J.Clml.2015.07.478 |
0.381 |
|
| 2014 |
Cheng F, Lienlaf M, Wang HW, Perez-Villarroel P, Lee C, Woan K, Rock-Klotz J, Sahakian E, Woods D, Pinilla-Ibarz J, Kalin J, Tao J, Hancock W, Kozikowski A, Seto E, et al. A novel role for histone deacetylase 6 in the regulation of the tolerogenic STAT3/IL-10 pathway in APCs. Journal of Immunology (Baltimore, Md. : 1950). 193: 2850-62. PMID 25108026 DOI: 10.4049/Jimmunol.1302778 |
0.466 |
|
| 2014 |
Knox T, Lienlaf M, Perez-Villarroel P, Lee C, Sahakian E, Powers JJ, Cheng F, Canales J, Marante D, Seto E, Sotomayor EM, Villagra A, Horna P. Selective Inhibition of HDAC6 Decreases Viability of Cutaneous T-Cell Lymphoma and Improves Immune Recognition Blood. 124: 5423-5423. DOI: 10.1182/Blood.V124.21.5423.5423 |
0.539 |
|
| 2014 |
Cheng F, Xia B, Sahakian E, Lwin T, Wang H, Xing L, Shah BD, PerezVillarroel P, LienlafMoreno M, Zhang Y, Quayle SN, Jones SS, Pinilla-Ibarz J, Villagra A, Sotomayor EM, et al. Selective Inhibition of Histone Deacetylase 6 (HDAC6) and HDAC3 As a Novel Therapeutic Strategy in Mantle Cell Lymphoma (MCL) Blood. 124: 5397-5397. DOI: 10.1182/Blood.V124.21.5397.5397 |
0.559 |
|
| 2014 |
Brayer JB, Sahakian E, Powers J, Meads MB, Deng S, Distler A, Alsina M, Nishihori T, Baz R, Villagra A, Pinilla-Ibarz J, Sotomayor EM, Shain KH. A Novel Role for Histone Deacetylase 11 (HDAC11) in B Cell Lymphopoiesis and Plasma Cell Survival in Multiple Myeloma Blood. 124: 4715-4715. DOI: 10.1182/Blood.V124.21.4715.4715 |
0.518 |
|
| 2014 |
Powers JJ, Maharaj KK, Sahakian E, Xing L, PerezVillarroel P, Knox T, Quayle S, Jones SS, Villagra A, Sotomayor EM, Pinilla-Ibarz J. Histone Deacetylase 6 (HDAC6) As a Regulator of Immune Check-Point Molecules in Chronic Lymphocytic Leukemia (CLL) Blood. 124: 3311-3311. DOI: 10.1182/Blood.V124.21.3311.3311 |
0.497 |
|
| 2014 |
Chen J, Sahakian E, Powers JJ, LienlafMoreno M, Xing L, Deng S, Distler A, Cheng F, Villagra A, Horna P, Sotomayor EM, Pinilla-Ibarz J. Histone Deacetylase 11 (HDAC11) As a Novel Transcriptional Regulator of C/EBP-β, in Immature Myeloid Cell to Myeloid Derived Suppressor Cell Transition Blood. 124: 225-225. DOI: 10.1182/Blood.V124.21.225.225 |
0.448 |
|
| 2014 |
Sahakian E, Brayer J, Powers J, Meads M, Deng S, Distler A, Alsina M, Nishihori T, Baz R, Villagra A, Pinilla-Ibarz J, Sotomayor E, Shain K. Abstract 5537: Histone deacetylase 11 (HDAC11) regulates B cell lymphopoiesis and potentiates plasma cell survival in multiple myeloma Cancer Research. 74: 5537-5537. DOI: 10.1158/1538-7445.Am2014-5537 |
0.504 |
|
| 2014 |
Woods DM, Sodre AL, Sahakian E, Powers J, Lienlaf-Moreno M, Perez-Villarroel P, Villagra A, Pinilla-Ibarz J, Sotomayor E. Abstract 4090: Inhibition of class I histone deacetylases promotes robust and durable enhancement of PDL1 expression in melanoma: Rationale for combination therapy Cancer Research. 74: 4090-4090. DOI: 10.1158/1538-7445.Am2014-4090 |
0.485 |
|
| 2013 |
Chavez JC, Sahakian E, Pinilla-Ibarz J. Ibrutinib: an evidence-based review of its potential in the treatment of advanced chronic lymphocytic leukemia. Core Evidence. 8: 37-45. PMID 23717217 DOI: 10.2147/Ce.S34068 |
0.446 |
|
| 2013 |
Chen J, Powers J, Rock-Klotz J, Deng S, Distler A, Cheng F, Villagra A, Sotomayor EM, Sahakian E, Pinilla-Ibarz J. Histone Deacetylase 11 (HDAC11) Is a Novel Regulator In The Expansion Of MDSCs Via The Transcription Factor C/EBP-β Blood. 122: 4887-4887. DOI: 10.1182/Blood.V122.21.4887.4887 |
0.415 |
|
| 2013 |
Woods DM, Woan K, Cheng F, Wang HW, Sahakian E, Powers J, Rock-Klotz J, Villagra A, Pinilla-Ibarz J, Sotomayor E. Abstract 692: Histone deacetylase 11 is an epigenetic regulator of CD8+ T-cell effector function and memory formation. Cancer Research. 73: 692-692. DOI: 10.1158/1538-7445.Am2013-692 |
0.456 |
|
| 2013 |
Sahakian E, Woan K, Villagra A, Sotomayor EM. Epigenetic Approaches: Emerging Role of Histone Deacetylase Inhibitors in Cancer Immunotherapy Cancer Immunotherapy: Immune Suppression and Tumor Growth: Second Edition. 353-372. DOI: 10.1016/B978-0-12-394296-8.00022-1 |
0.387 |
|
| 2012 |
Cheng F, Wang H, Horna P, Wang Z, Shah B, Sahakian E, Woan KV, Villagra A, Pinilla-Ibarz J, Sebti S, Smith M, Tao J, Sotomayor EM. Stat3 inhibition augments the immunogenicity of B-cell lymphoma cells, leading to effective antitumor immunity. Cancer Research. 72: 4440-8. PMID 22728650 DOI: 10.1158/0008-5472.Can-11-3619 |
0.497 |
|
| 2012 |
Woan KV, Sahakian E, Sotomayor EM, Seto E, Villagra A. Modulation of antigen-presenting cells by HDAC inhibitors: implications in autoimmunity and cancer. Immunology and Cell Biology. 90: 55-65. PMID 22105512 DOI: 10.1038/Icb.2011.96 |
0.45 |
|
| 2012 |
Woods DM, Woan KV, Sahakian E, Powers J, Cheng F, Wang H, Rock-Klotz J, Weber JS, Villagra A, Pinilla-Ibarz J, Sotomayor EM. Histone Deacetylase 11 (HDAC11) Regulates Cytotoxic T-Cell Function and Memory Phenotype Blood. 120: 840-840. DOI: 10.1182/Blood.V120.21.840.840 |
0.472 |
|
| 2012 |
Cheng F, Wang Z, Wang H, Lienlaf M, Woan KV, Perez-Villarroel P, Rock-Klotz J, Sahakian E, Knox T, Woods DM, Powers J, Han R, Merino O, Deng S, Marante D, et al. Physical Interaction of Histone Deacetylase 6 (HDAC6) with STAT3 Regulates IL-10 Gene Expression and Immune Tolerance Mediated by Antigen-Presenting Cells (APCs) Blood. 120: 829-829. DOI: 10.1182/Blood.V120.21.829.829 |
0.524 |
|
| 2012 |
Sahakian E, Powers J, Horna P, Rock-Klotz J, Deng S, Woods DM, Nguyen M, Woan KV, Cheng F, Villagra A, Gabrilovich D, Sotomayor EM, Pinilla-Ibarz J. Novel Role of Histone Deacetylase 11 (HDAC11) in Hematopoiesis Blood. 120: 4728-4728. DOI: 10.1182/Blood.V120.21.4728.4728 |
0.431 |
|
| 2012 |
Powers J, Sahakian E, Dubovsky JA, Farnum T, Berchmans E, McNeel DG, Skikne BS, MacBeth KJ, Komrokji RS, Pinilla-Ibarz J. Inducible Expression of Cancer Testis Antigens in Myelodysplastic Syndrome (MDS) Patients Following Treatment with an Oral 5-Azacytidine Blood. 120: 3828-3828. DOI: 10.1182/Blood.V120.21.3828.3828 |
0.307 |
|
| 2012 |
Wang H, Cheng F, Wang Z, Lienlaf M, Perez-Villarroel P, Knox T, Sahakian E, Pinilla-Ibarz J, Horna P, Chen-Kiang S, Martin P, Bergman J, Kozikowski A, Villagra A, Tao J, et al. Inhibition of Histone Deacetylase 6 (HDAC6) Disrupts the Tolerogenic STAT3 Signaling Pathway and Augments Antitumor Immune Responses in Mantle Cell Lymphoma (MCL) Blood. 120: 3724-3724. DOI: 10.1182/Blood.V120.21.3724.3724 |
0.558 |
|
| 2012 |
Sahakian E, Rock-Klotz J, Shah BD, Powers J, Cultrera JL, Deng S, Woods DM, Nguyen M, Cheng F, Wang H, Perez-Villarroel P, Lienlaf M, Knox T, Chen-Kiang S, Villagra A, et al. Combination of ACY1215, a Selective Histone Deacetylase 6 (HDAC6) Inhibitor with the Bruton Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, Represents a Novel Therapeutic Strategy in Mantle Cell Lymphoma (MCL) Blood. 120: 1660-1660. DOI: 10.1182/Blood.V120.21.1660.1660 |
0.557 |
|
| 2012 |
Sahakian E, Powers J, Rock-Klotz J, Marsilio A, Woan K, Merino O, Gill A, Deng S, Cheng F, Villagra A, Luekette N, Seto E, Borrello I, Sotomayor E, Pinilla JI. Abstract 4260: Histone deacetylase 11 (HDAC11) as a novel therapeutic target in the regulation of myeloid-derived suppressor cell (MDSC) Cancer Research. 72: 4260-4260. DOI: 10.1158/1538-7445.Am2012-4260 |
0.492 |
|
| 2012 |
Woan KV, Vazquez L, Rock-Klotz J, Wang Z, Cheng F, Wang H, Woods D, Sahakian E, Perez P, Lienlaf M, Achille A, Bergman J, Kalin J, Gill A, Powers J, et al. Abstract 3555: Histone deacetylase 6 as a novel regulator of the immunogenicity and aggressiveness of melanoma Cancer Research. 72: 3555-3555. DOI: 10.1158/1538-7445.Am2012-3555 |
0.521 |
|
| 2012 |
Woods DM, Woan KV, Wang H, Cheng F, Wang Z, Vazquez L, Perez P, Lienlaf M, Rock-Klotz J, Sahakian E, Powers J, Deng S, Oscar M, Atadja P, Seto E, et al. Abstract 3554: The histone deacetylase inhibitor LBH589 augments anti-tumor immunity through direct effects on tumor and immune cells leading to impaired tumor progressionin vivo Cancer Research. 72: 3554-3554. DOI: 10.1158/1538-7445.Am2012-3554 |
0.513 |
|
| 2011 |
Wang H, Cheng F, Woan K, Sahakian E, Merino O, Rock-Klotz J, Vicente-Suarez I, Pinilla-Ibarz J, Wright KL, Seto E, Bhalla K, Villagra A, Sotomayor EM. Histone deacetylase inhibitor LAQ824 augments inflammatory responses in macrophages through transcriptional regulation of IL-10. Journal of Immunology (Baltimore, Md. : 1950). 186: 3986-96. PMID 21368229 DOI: 10.4049/Jimmunol.1001101 |
0.461 |
|
| 2011 |
Wang H, Wang Z, Cheng F, Woan KV, Rock-Klotz J, Sahakian E, Powers J, Javier P, Bergman J, Villagra A, Kozikowski A, Sotomayor EM. Tubastatin A, a Selective HDAC6 Inhibitor, Enhances Antigen-Presenting Cell (APC) Function and Restores the Responsiveness of Anergic CD4+ T Cells Blood. 118: 520-520. DOI: 10.1182/Blood.V118.21.520.520 |
0.511 |
|
| 2011 |
Cheng F, Wang Z, Wang H, Woan KV, Sahakian E, Klotz JR, Wang L, Han R, Merino O, Deng S, Vazquez L, Gill AS, Marante D, Powers J, Hancock WW, et al. Epigenetic Modulation of STAT3 by Histone Deacetylase 6 (HDAC6) Regulates IL-10 Gene Expression and Immune Tolerance Mediated by Antigen-Presenting Cells (APCs) Blood. 118: 519-519. DOI: 10.1182/Blood.V118.21.519.519 |
0.431 |
|
| 2011 |
Woan KV, Wang D, Wang Z, Cheng F, Vazquez L, Woods D, Yu Y, Sahakian E, Wang H, Telles E, Peng L, Wang L, Hancock WW, Blazar BR, Luetteke N, et al. Histone Deacetylase 11 (HDAC11) Is a Regulatory Checkpoint of T-Cell Function: Implications for T-Cell Adoptive Immunotherapy Blood. 118: 359-359. DOI: 10.1182/Blood.V118.21.359.359 |
0.483 |
|
| 2011 |
Sahakian E, Powers J, Rock-Klotz J, Adriani M, Woan KV, Merino O, Gill AS, Deng S, Cheng F, Villagra A, Luetteke N, Seto E, Sotomayor EM, Borrello IM, Pinilla-Ibarz J. A Novel Role of Histone Deacetylase 11 (HDAC11) in Regulation of Myeloid-Derived Suppressor Cell (MDSC) Expansion Blood. 118: 2439-2439. DOI: 10.1182/Blood.V118.21.2439.2439 |
0.485 |
|
| 2011 |
Powers J, Padron E, Dubovsky J, Berchmans E, Farnum T, Bai F, Sahakian E, Ahmed J, Komrokji RS, Lancet JE, List AF, McNeel DG, Dessureault S, Antonia S, Sotomayor EM, et al. Enhanced Immunological Responses Following K562/GM-CSF/CD40L Vaccine Plus Lenalidomide in High-Risk Myelodysplastic Syndrome Blood. 118: 1725-1725. DOI: 10.1182/Blood.V118.21.1725.1725 |
0.306 |
|
| 2011 |
Sahakian E, Shah BD, Powers J, Deng S, Merino O, Gill AS, Rock-Klotz J, Woan KV, Vazquez L, Wang H, Chen-Kiang S, Tao J, Villagra A, Pinilla-Ibarz J, Sotomayor EM. The Opposing Role of Histone Deacetylase 10 (HDAC10) and HDAC11 in Proliferation/Survival of Mantle Cell Lymphoma (MCL) and Chronic Lymphocytic Leukemia (CLL) Blood. 118: 1363-1363. DOI: 10.1182/Blood.V118.21.1363.1363 |
0.547 |
|
| 2010 |
Kodumudi KN, Woan K, Gilvary DL, Sahakian E, Wei S, Djeu JY. A novel chemoimmunomodulating property of docetaxel: suppression of myeloid-derived suppressor cells in tumor bearers. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 4583-94. PMID 20702612 DOI: 10.1158/1078-0432.Ccr-10-0733 |
0.435 |
|
| 2010 |
Zhong B, Sallman DA, Gilvary DL, Pernazza D, Sahakian E, Fritz D, Cheng JQ, Trougakos I, Wei S, Djeu JY. Induction of clusterin by AKT--role in cytoprotection against docetaxel in prostate tumor cells. Molecular Cancer Therapeutics. 9: 1831-41. PMID 20501799 DOI: 10.1158/1535-7163.Mct-09-0880 |
0.529 |
|
| 2009 |
Mediavilla-Varela M, Pacheco FJ, Almaguel F, Perez J, Sahakian E, Daniels TR, Leoh LS, Padilla A, Wall NR, Lilly MB, De Leon M, Casiano CA. Docetaxel-induced prostate cancer cell death involves concomitant activation of caspase and lysosomal pathways and is attenuated by LEDGF/p75. Molecular Cancer. 8: 68. PMID 19715609 DOI: 10.1186/1476-4598-8-68 |
0.559 |
|
| 2009 |
Parrish YK, Baez I, Milford TA, Benitez A, Galloway N, Rogerio JW, Sahakian E, Kagoda M, Huang G, Hao QL, Sevilla Y, Barsky LW, Zielinska E, Price MA, Wall NR, et al. IL-7 dependence in human B lymphopoiesis increases during progression of ontogeny from cord blood to bone marrow Journal of Immunology. 182: 4255-4266. PMID 19299724 DOI: 10.4049/Jimmunol.0800489 |
0.357 |
|
| 2008 |
Zemskova M, Sahakian E, Bashkirova S, Lilly M. The PIM1 kinase is a critical component of a survival pathway activated by docetaxel and promotes survival of docetaxel-treated prostate cancer cells. The Journal of Biological Chemistry. 283: 20635-44. PMID 18426800 DOI: 10.1074/Jbc.M709479200 |
0.653 |
|
| 2007 |
Parrish YK, Baez I, Milford TM, Rogerio JW, Sahakian E, Kagoda M, Benitez A, Huang G, Payne KJ. Human B Cell Development from Adult Bone Marrow Is Profoundly Dependent on IL-7 Due to Decreased B Lymphoid Generative Capacity. Blood. 110: 3266-3266. DOI: 10.1182/Blood.V110.11.3266.3266 |
0.359 |
|
| 2003 |
Payne KJ, Huang G, Sahakian E, Zhu JY, Barteneva NS, Barsky LW, Payne MA, Crooks GM. Ikaros isoform x is selectively expressed in myeloid differentiation. Journal of Immunology (Baltimore, Md. : 1950). 170: 3091-8. PMID 12626565 DOI: 10.4049/Jimmunol.170.6.3091 |
0.37 |
|
| Show low-probability matches. |